目的: 探讨核苷酸切除修复交叉互补基因1(excision repair crosscomplementing 1, ERCC1)在鼻咽癌(nasopharyngeal carcinoma, NPC)组织中的表达及其与顺铂化疗敏感性的关系。方法: 选取广西南溪山医院2006年6月至2008年6月确诊的82例中晚期NPC患者，接受顺铂+5FU的基础化疗加放疗，应用免疫组化法检测NPC癌组织中ERCC1蛋白的表达及其中的34例患者癌旁上皮组织(对照组)中ERCC1蛋白的表达。结果：NPC癌旁上皮组织中ERCC1的阳性率为88.2%，显著高于NPC癌组织中ERCC1的阳性率63.4% (P<0.05)。ERCC1表达与NPC患者年龄有关(P<0.05)，而与性别、T分期、N分期、M分期无关（P>0.05）。ERCC1蛋白表达阳性的NPC患者化疗有效率为36.5%，ERCC1阴性患者化疗有效率为63.3%，两者差异有统计学意义(P<0.05)。结论：ERCC1在中晚期NPC癌组织中低表达，ERCC1表达与顺铂+5FU方案的疗效呈负相关，检测ERCC1表达有助于预测NPC患者对顺铂化疗的敏感性。

Objective ：To examine the expression of ERCC1 (excision repair crosscomplementing 1, ERCC1) in nasopharyngeal carcinoma (NPC) tissues and its relationship with chemosensitivity to cisplatinbased chemotherapy. Methods: Eightytwo patients with advanced NPC, who were diagnosed at Nanxisan hospital of Guangxizhuang autonomous region from June 2006 to June 2008, were treated with cisplatin+5FU regimen. The expression of ERCC1 in 82 nasopharyngeal carcinoma (NPC) tissues and in 34 adjacent normal tissues was detected by immunohistochemistry assay. Results: The positive rate of ERCC1 expression in NPC adjacent normal tissues was significantly higher than that in NPC tissues (88.2% vs 63.4%, P<0.05). Expression of ERCC1 in NPC was positively correlated with patients′ age, but not with gender, T stage, N stage and M stage (P>0.05). The efficacy rate of cisplatinbased chemotherapy in ERCC1 positive NPC patients was significantly higher than that in ERCC1 negative patients (63.3% vs 36.5%, P<0.05). Conclusion: ERCC1 is lowly expressed in advanced NPC tissues; its expression is negatively correlated with the chemosensitivity to cisplatin+5FU regimen. ERCC1 can be used to predict the sensitivity of NPC patients to cisplatinbased chemotherapy.

广西桂林市科学研究与技术开发计划项目(No.20070514)